News | December 16, 2007

PCI Guidline Update Stresses Long-Term Anticoagulant Therapy

December 17, 2007 - Patients treated with drug-eluting stents must take a combination of aspirin and the clot-reducing drug clopidogrel for at least one year, and possibly longer, after stent implantation, according to a guideline update published online today in the journals of the Society for Cardiovascular Angiography and Interventions (SCAI), American College of cardiology (ACC) and American Heart Association (AHA).

"For most patients suffering a heart attack, angioplasty and implantation of a stent is a life-saving procedure," said SCAI President Bonnie Weiner, M.D. "However, both patients and the medical community need to understand how essential dual anticoagulant therapy is after receiving a drug-eluting stent. That's the purpose of this update -- to stress this and other evidence published relatively recently."

The update specifically addresses findings from studies published through late 2006. One of the concerns that arose during this period was about a slightly higher risk of blood clots forming inside drug-eluting stents. These clots are a rare but serious complication of drug-eluting stents and must be prevented with a strict regimen of aspirin plus the clot-reducing drug clopidogrel for at least one year after the artery is opened with a stent. "By emitting tiny amounts of medication, drug-eluting stents reduce the regrowth of scar tissue and other build-up that could renarrow the artery, creating a need for a repeat angioplasty," explained Dr. Weiner. "While we don’t want to understate the precautions that should be taken to prevent clots, we also want to factor in the benefits of these newer devices.

"If there are doubts about whether the patient can stay on the dual-antiplatelet therapy for at least one year, then a bare metal stent is probably the better choice," stresses Dr. Weiner. "We want to encourage physicians to think about the patient's history with compliance to drug therapy as well as other potential obstacles, such as planned surgeries, that might lead them to not take their aspirin and clopidogrel. In those cases, the update calls for a bare metal stent or balloon angioplasty with provisional stent implantation."

The guideline update also considers OAT (Open Artery Trial) and the earlier ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) study, two randomized clinical trials that looked at whether to open totally blocked arteries in patients who had suffered a heart attack between three and 28 days earlier. "OAT looked at patients with a completely blocked artery who had suffered a heart attack between 72 hours and 28 days earlier, but had neither serious chest pain nor evidence of ischemia," said Dr. Weiner. "Considering the findings of ICTUS, the writing committee suggests that in patients with unstable angina or the milder form of heart attack known as non-ST-segment elevation myocardial infarction (NSTEMI), risk stratification is critical to determining the optimal approach to patient care and that coronary angiography and PCI improve outcomes in high-risk patients."

"The OAT findings might rule out a small subset of patients who might have otherwise been candidates for angioplasty," said Douglass Morrison, a writing committee member and an OAT investigator, "but it also points to a very important issue: time. The real emphasis needs to be on educating patients to call 9-1-1 if they are having heart attack symptoms so they can get to the emergency department in time to have PCI when it will do the most good."

The update also strengthens the earlier guideline’s recommendations about smoking cessation, exposure to second-hand smoke, medical management of high cholesterol and high blood pressure, coordinated care of diabetic patients and getting a flu shot. The update does not address in detail when PCI should be used for patients with chronic stable angina. The more recent studies addressing this issue are still being tested in ongoing studies and debated in the medical literature.

For more information: www.scai.org

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
Overlay Init